Verigat Tablet 2.5 mg contains Vericiguat, an innovative soluble guanylate cyclase (sGC) stimulator used for the management of chronic heart failure, particularly in patients with reduced ejection fraction who remain symptomatic despite standard therapy. Vericiguat helps improve heart function, reduce hospitalization, and enhance quality of life for patients with heart failure by targeting the underlying pathophysiological mechanisms that impair cardiac performance.

Chronic heart failure is a progressive condition characterized by the heart’s inability to pump sufficient blood to meet the body’s needs. Symptoms often include fatigue, shortness of breath, and fluid retention, which significantly impact daily life. Vericiguat works by stimulating the NO-sGC-cGMP pathway, promoting vasodilation and improving myocardial efficiency.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

How Verigat Tablet Works

Vericiguat acts by enhancing the activity of soluble guanylate cyclase (sGC), an enzyme critical in the nitric oxide (NO) signaling pathway:

• Stimulates sGC to increase cyclic guanosine monophosphate (cGMP) production

• Promotes vasodilation, reducing vascular resistance and afterload

• Improves cardiac output and myocardial efficiency

• Reduces cardiac remodeling and stress on the heart

• Complements standard heart failure therapies for better overall outcomes

By targeting the NO-sGC-cGMP pathway, Verigat addresses both the symptoms and progression of heart failure.

Indications

Verigat Tablet 2.5 mg is indicated for:

• Chronic heart failure with reduced ejection fraction (HFrEF)

• Patients who remain symptomatic despite standard therapy, including ACE inhibitors, ARBs, beta-blockers, and mineralocorticoid receptor antagonists

• Reduction of the risk of heart failure-related hospitalizations

• Improvement of overall cardiovascular outcomes in chronic heart failure management

It is prescribed under the supervision of a cardiologist, especially in patients with advanced or high-risk heart failure.

Dosage and Administration

• The starting dose is usually 2.5 mg once daily, taken orally, with or without food.

• Dose titration may be performed gradually based on tolerance, blood pressure, and clinical response.

• Tablets should be swallowed whole with water; do not crush or chew.

• Regular follow-up and monitoring of blood pressure, kidney function, and heart rate are recommended during therapy.

Adherence to the prescribed dose and schedule is critical to achieving maximum therapeutic benefit.

Precautions

• Use under medical supervision, especially in patients with hypotension, severe renal or hepatic impairment, or electrolyte imbalances.

• Inform your physician about all medications, as Vericiguat may interact with certain drugs that affect blood pressure or heart function.

• Not recommended during pregnancy or breastfeeding unless specifically advised by a healthcare professional.

• Patients should monitor for signs of dizziness or low blood pressure.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects may include:

• Hypotension (low blood pressure)

• Dizziness or lightheadedness

• Headache

• Fatigue or weakness

Rare but serious adverse effects may include severe hypotension, syncope, or worsening heart failure. Immediate medical attention is required if severe symptoms occur.

Storage

Store Verigat Tablet 2.5 mg in a cool, dry place, away from light and moisture. Keep out of reach of children.

Verigat Tablet 2.5 mg is a clinically proven therapy for improving heart function, reducing hospitalization, and enhancing the quality of life in patients with chronic heart failure, complementing standard treatment regimens.